reSee.it Video Transcript AI Summary
Speaker 0 describes the plasma-derived hepatitis B vaccine as derived from “the most dangerous starting material” and asserts the starting material was blood heavily contaminated with HIV, collected from New York heroin users during what is recognized as the world’s first AIDS outbreak. He notes the vaccine’s development began with funds from Doctor Fauci’s agency, in collaboration with Tuskegee researchers, to cross-connect arteries of tranquillised chimpanzees and comatose humans, with mixed raw blood flowing between groups of chimps and humans to train the chimps’ immune systems on human hepatitis virus. The vaccine inventors warned it might work the other way as well and claims several chimpanzees tested positive for ancestors to HIV and Kaposi’s sarcoma herpes virus, the deadly combination behind AIDS; this serial passage between species is called gain of function. He concludes this created the safest vaccine we’ve ever used.
Speaker 1 adds a claim about a hidden starting point: the blood used was heavily contaminated with HIV from New York heroin users, and that the vaccine’s development involved financing from Fauci’s agency and collaboration with Tuskegee researchers to cross-link chimpanzee and human circulatory systems. He states that the serial passage of viruses between species is now called gain of function and asserts this process produced HIV and Kaposi’s sarcoma herpes virus, and suggests the vaccine’s safety is paradoxical given these origins.
Speaker 2 emphasizes responsibility and risk, noting AIDS’ cause was unknown at the time but fear centered on potential contamination of the vaccine with whatever caused AIDS. HIV was “sort of hanging over this vaccine like a cloud,” though he claims HIV couldn’t survive the treatments given to the vaccine.
Speaker 0 transitions to Part II, a deep dive into the vaccine timeline, aiming to quickly reach the AIDS timeline ramifications.
Speaker 3 provides a timeline framework: well-documented events through May 1983 to set the stage for two fiercely contested events now resolved by a federal investigation.
Speaker 2 lists milestones:
- 1950s: The world’s earliest confirmed HIV-positive being is a chimpanzee used to develop hepatitis B vaccines.
- 1960s: Chimpanzees and New York heroin users cross-transfuse raw blood to generate chimpanzee antigens to fight human hepatitis.
- 1972: Scientists at Doctor Fauci’s agency announce chimpanzee antigens protect humans from hepatitis B; first patent filed for a human vaccine made from chimpanzee antigens.
- 1973: The world’s first recognized AIDS outbreak occurs among New York heroin users, the first group injected with chimpanzee plasma.
- 1974: Thirteen thousand New York gay men recruited to test the vaccines.
- 1975: NYBC and Merck file three patents, citing five vaccine examples all made from pure chimpanzee antigens; a circular extraction method akin to dialysis to extract large amounts of antigens for mass production.
- 1978: After years of testing, nationwide placebo-controlled trials begin on gay men with NYBC’s New York trial and CDC trials mainly in California; first HIV-positive blood samples found in gay men, all collected from the cohort, all of the never-before-seen subtype B.
- 1979: September—ten months into the trial—the scientist in charge wants to abort due to an unexplainable flare-up in precisely 11 participants who received the vaccine; aborting would harm the vaccine’s reputation. CDC soon reports unexplainable Kaposi’s sarcoma cases in gay men, noting that precisely eleven had the flare-up as of September 1979; by December, 19 cases and the first death, marking the onset of the world's second AIDS outbreak affecting the second group inoculated with chimpanzee plasma-derived vaccines.
- 1981: A cancer researcher suggests a new infectious agent with a 50% mortality rate may be causing Kaposi’s sarcoma cases in vaccine trial sites and claims it was transmitted in the vaccine as disease progression occurred quickly in trial participants; trial scientists confirm incubation periods differ and are longer in gay men not in the trial. In the next 15 months, another 593 cases emerge and 41% die. Merck announces Heptavax B, a third US brand for domestic market; original HBVax and NYBC B Vax offered only overseas; a compromise to get FDA approval makes the new version from human blood, but without the circular chimpanzee extraction method it’s “too expensive” for large-scale use.
- 1982: CDC names the disease AIDS; CDC asserts the FDA-approved vaccine uses only human blood, distancing it from earlier vaccines; WHO warns AIDS may be caused by a virus in the vaccine’s plasma.
- May 1983: French scientists identify the causal virus, enabling testing of archived blood samples; it was a chimpanzee virus, and KS lesions required co-infection with a second virus found in those chimpanzees. This discovery enables verifying the AIDS origin theory: vaccine transmission by comparing HIV rates between men randomly given the hepatitis B vaccine versus a placebo during the trials.
Speaker 3 notes two pivotal events in their chimp vax preprint, now settled, and states that in June 1983 two Fauci-associated scientists claimed infection rates in the New York trial were similar between vaccine and placebo; internally, they say Fauci’s scientists spread disinformation to defend the chimpanzee vaccine invention. Speaker 2 contends that the CDC claimed no difference in rates in 1984 but that the private study remains unreleased; the analysis implies nearly all HIV infections occurred in vaccinated participants, not placebo, based on limited data and interpretation. The narrative argues the CDC private study would have shown high HIV rates among the vaccine group, but details were obscured. It alleges the CDC’s withheld study used skewed comparisons to mask vaccine-associated HIV transmission.
Speaker 3 briefly references Africa’s rollout in 1984, claiming AIDS emerged there a year after a symposium and that FDA officials shifted from chimpanzee vaccines to the human-blood Heptavax, enabling continued overseas sales. It asserts chimpanzee-based vaccines were widely used in poor countries by 1986, with Africa’s initial infections concentrated in newborns and young women; the WHO suppressed findings that HIV spread via medical injections, not needles alone, to protect immunization programs. Retroactive testing allegedly shows HIV was not present in most African countries before vaccination; after vaccination began, infection rates rose in certain regions. The speaker notes a group, ChimpFacts, as a best account of probable HIV origins, but mainstream preprint servers rejected it.